ALPHARETTA, Ga., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced that Rick McElheny has been named Vice President, Business Development.
Mr. McElheny is a highly accomplished executive with expertise in business development, finance, market research, strategic planning, and supply chain management within the specialty pharmaceutical industry. Most recently, he served as Senior Vice President of Corporate Development at Sarvint Technologies. Prior to Sarvint, Mr. McElheny founded and served as Vice President of Corporate Development and Supply Chain at Vidara Therapeutics. He has also held roles in business development, market research and supply chain management at Meda Pharmaceuticals, Schering-Plough, and Johnson & Johnson. In Mr. McElheny’s role as Vice President, Business Development, he will be responsible for Clearside’s business development outreach, continuing existing collaborations and establishing new collaborations for Clearside’s product candidates and programs.
“I am delighted to have someone with Rick’s caliber join the Clearside team to build out future collaborations with innovative companies as we seek to develop transformative, elegant, precise solutions to restore and preserve vision,” said Daniel White, President and Chief Executive Officer of Clearside Biomedical. “Rick is an accomplished professional in developing partnerships that enhance shareholder value and I am confident he will do the same at Clearside.”
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a publicly traded, ophthalmic biopharmaceutical company that envisions a world without blindness. Clearside relentlessly pursues transformative, elegant, precise solutions to restore and preserve vision. Clearside is developing advanced clinical and pre-clinical product candidates using a proprietary treatment approach offering unprecedented access to the back of the eye through the suprachoroidal space (SCS™). This offers potentially significant treatment to patients suffering from sight threatening diseases like uveitis, retinal vein occlusion, wet age-related macular degeneration and diabetic macular edema. To learn more about how Clearside is changing ophthalmology, please visit us at www.clearsidebio.com
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Clearside’s current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of Clearside’s product candidates and Clearside’s entry into future collaborations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Clearside’s reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in Clearside’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, filed with the U.S. Securities and Exchange Commission (“SEC”) on August 12, 2016 and Clearside’s other Periodic Reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Clearside as of the date of this release, and Clearside assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
Source:Clearside Biomedical, Inc.